Skip to main content

Table 3 Patient and tumor characteristics for the six genomic subtypes

From: Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics

 

Basal-complex

n(%)

17q12

n(%)

Luminal-complex

n(%)

Luminal-simple

n(%)

Amplifier

n(%)

Mixed

n(%)

Group size

67

51

105

46

52

38

Hereditary status

      

   BRCA1-mutated

17 (25)

0

1 (1)

0

2 (4)

2 (5)

   BRCA2-mutated

5 (7)

1 (2)

25 (24)

0

0

1 (3)

   Familial

15 (22)

19 (37)

38 (36)

23 (50)

29 (56)

8 (21)

   Sporadic

30 (45)

31 (61)

41 (39)

23 (50)

21 (40)

27 (71)

Clinical parameters

      

   ER+

7 (10)

19 (37)

91 (87)

44 (96)

40 (77)

26 (68)

   ER-

56 (84)

29 (57)

11 (10)

2 (4)

10 (19)

11 (29)

   LN+

19 (28)

25 (49)

42 (40)

12 (26)

20 (38)

19 (50)

   LN-

43 (64)

19 (37)

50 (48)

32 (70)

28 (54)

18 (47)

Mean tumor size (mm ± SD)

27 ± 12

31 ± 21

26 ± 17

21 ± 10

25 ± 13

25 ± 11

   Histologic grade 1

1 (1)

1 (2)

5 (5)

9 (20)

8 (15)

2 (5)

   Histologic grade 2

5 (7)

14 (27)

31 (30)

21 (46)

19 (37)

10 (26)

   Histologic grade 3

42 (63)

19 (37)

26 (25)

4 (9)

9 (17)

6 (16)

Molecular subtypes by Hu et al. [4]

      

   Basal-like

56 (84)

5 (10)

4 (4)

0

8 (15)

6 (16)

   HER2-enriched

0

30 (59)

3 (3)

0

0

1 (3)

   Luminal B

1 (1)

3 (6)

48 (46)

1 (2)

12 (23)

5 (13)

   Luminal A

1 (1)

6 (12)

31 (30)

33 (72)

12 (23)

12 (32)

   Normal-like

3 (4)

6 (12)

3 (3)

6 (13)

10 (19)

6 (16)

   Unclassified

6 (9)

1 (2)

16 (15)

6 (13)

10 (19)

8 (21)

FGA (mean %)

      

   Overall FGA (%)

53

26

37

19

31

29

   Gain FGA (%)

18

12

15

9

15

12

   Loss FGA (%)

34

14

22

10

16

18

  1. ER, Estrogen receptor; FGA, fraction of the genome altered; LN, lymph node.